Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2022-12-09 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
关于可转债投资者适当性要求的风险提示性公告
Regulatory Filings Classification · 95% confidence The document is a risk warning announcement related to the suitability requirements for investors in a convertible bond issued by Shenzhen Microchip Biotechnology Co., Ltd. It details the issuance and listing of the convertible bonds, regulatory approvals, and the risk that investors not meeting certain suitability criteria cannot convert the bonds into shares. The document does not contain financial statements or detailed financial data but serves as a regulatory disclosure and risk notice. It is not an annual report, earnings release, or financial supplement. It is also not a report publication announcement since it contains substantive content about the bond issuance and investor risk. The document fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about the convertible bond issuance and associated investor risk disclosures that do not fit other specific categories.
2022-12-09 Chinese
关于持股5%以上股东大宗交易减持结果公告
Major Shareholding Notification Classification · 100% confidence The document is a formal announcement regarding the completion of a large block share transaction by a shareholder holding more than 5% of the company's shares. It details the reduction in shareholding by 博奥生物集团有限公司 through a block trade to its controlling shareholder. The document includes specifics such as share quantities, percentages, transaction dates, and prices. It is not a financial report, earnings release, or management discussion, but rather a notification of a significant shareholder's shareholding change. This fits the definition of a Major Shareholding Notification (MRQ). The document length is short and focused solely on this shareholding change, confirming it is not a full report or announcement of a report publication.
2022-12-02 Chinese
关于持股5%以上股东减持股份计划的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding a shareholding reduction plan by a shareholder holding more than 5% of the company's shares. It details the shareholder's identity, the number and percentage of shares held, the planned reduction amount, the method of reduction, the timing, and the reasons for the reduction. It also includes risk disclosures and compliance with relevant regulations. There are no financial statements or performance data, nor is this a report or presentation. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2022-11-25 Chinese
关于使用自有美元资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen Microchip Biotechnology Co., Ltd. regarding the use of its own idle US dollar funds for cash management. It details the board's approval, investment purpose, amount, duration, types of investment products, risk control measures, and opinions from independent directors and the supervisory board. The document is a formal disclosure about a financing or capital management activity, specifically about using idle funds for investment in safe, liquid products to increase returns. It is not a full financial report, audit, earnings release, or management discussion. It is not a report publication announcement or a certification. The content fits best under Capital/Financing Update (CAP) as it relates to the company's capital management and investment of funds.
2022-11-09 Chinese
独立董事关于第二届董事会第二十四次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding a specific board meeting agenda item about the use of idle USD funds for cash management. It references the company's board meeting and legal regulations but does not contain financial statements or detailed financial data. The document is short (780 characters) and focuses on governance and board approval matters rather than financial results or reports. This fits best under Board/Management Information (MANG), which covers announcements related to board decisions and management matters.
2022-11-09 Chinese
第二届监事会第十五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Shenzhen Microchip Biotechnology Co., Ltd. regarding the approval of a cash management proposal using the company's own USD funds. It includes details about the meeting date, attendance, voting results, and legal compliance. The document is an official announcement of a board meeting decision rather than a full financial report or detailed management discussion. It does not contain financial statements or detailed financial data. The document length is short (894 characters), and it is a formal announcement of a board resolution. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous official announcements that do not fit other categories.
2022-11-09 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.